Loading...
Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.
Shireen, R Brennan, D Flannelly, G Fennelly, D Lenehan, P Foley, M
Shireen, R
Brennan, D
Flannelly, G
Fennelly, D
Lenehan, P
Foley, M
Advisors
Editors
Other Contributors
Date
2012-02
Date Submitted
Keywords
Other Subjects
Subject Mesh
Adenocarcinoma
Adenocarcinoma, Mucinous
Chemotherapy, Adjuvant
Cystadenocarcinoma, Serous
Female
Humans
Neoplasm, Residual
Ovarian Neoplasms
Paclitaxel
Adenocarcinoma, Mucinous
Chemotherapy, Adjuvant
Cystadenocarcinoma, Serous
Female
Humans
Neoplasm, Residual
Ovarian Neoplasms
Paclitaxel
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Article6277.pdf
Adobe PDF, 11.59 KB
Alternative Titles
Publisher
Abstract
Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.
Language
en
ISSN
0332-3102
eISSN
ISBN
DOI
PMID
22455239